Edition:
United States

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

0.58USD
15 Jun 2018
Change (% chg)

$0.02 (+3.23%)
Prev Close
$0.57
Open
$0.58
Day's High
$0.58
Day's Low
$0.56
Volume
281,870
Avg. Vol
195,606
52-wk High
$2.68
52-wk Low
$0.42

Chart for

About

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition,... (more)

Overall

Beta: 2.89
Market Cap(Mil.): $24.51
Shares Outstanding(Mil.): 41.93
Dividend: --
Yield (%): --

Financials

  PULM.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -0.96 -- --
ROI: -152.34 -5.87 13.17
ROE: -168.96 -7.71 15.15

BRIEF-Pulmatrix Q1 Loss Per Share $0.24

* QTRLY LOSS PER SHARE $0.24 Source text for Eikon: Further company coverage:

May 11 2018

BRIEF-Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook On Pulmonary Disease Pipeline

* PULMATRIX REPORTS 2017 FINANCIAL RESULTS; PROVIDES 2018 OUTLOOK ON PULMONARY DISEASE PIPELINE

Mar 13 2018

BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole

* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE

Feb 12 2018

Earnings vs. Estimates